I never counted AMS out of calculations - the opportunities too valuable to ignore, even if there are competitors. We have a significant advantage given the safety/tolerability profile, not to mention the ease of administration compared to the lumbar puncture method (sorry if I have the technicals wrong in that description).
it would seem to me that 2591 could be used as a primary and adjunct therapy in AMS.
would love to see @KJK’s numbers with the firm reinclusion.
Ann: J.P. Morgan Healthcare Conference recap, page-15
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$17.29 |
Change
0.660(3.97%) |
Mkt cap ! $2.178B | |||
| Open | High | Low | Value | Volume |
| $16.80 | $17.34 | $16.63 | $9.078M | 529.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1334 | $17.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.33 | 2245 | 3 |
View Market Depth
| Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |